Kronos Bio Stock Total Asset
| KRON Stock | USD 0.95 0.01 1.04% |
Kronos Bio fundamentals help investors to digest information that contributes to Kronos Bio's financial success or failures. It also enables traders to predict the movement of Kronos Stock. The fundamental analysis module provides a way to measure Kronos Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kronos Bio stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 213.3 M | 279.9 M |
Kronos | Total Asset |
Kronos Bio Company Total Asset Analysis
Kronos Bio's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Kronos Bio Total Asset | 213.28 M |
Most of Kronos Bio's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kronos Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kronos Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Kronos Bio is extremely important. It helps to project a fair market value of Kronos Stock properly, considering its historical fundamentals such as Total Asset. Since Kronos Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kronos Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kronos Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Kronos Total Asset Historical Pattern
Today, most investors in Kronos Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kronos Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kronos Bio total asset as a starting point in their analysis.
Kronos Bio Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Kronos Total Assets
Total Assets |
|
Based on the latest financial disclosure, Kronos Bio has a Total Asset of 213.28 M. This is 97.16% lower than that of the Biotechnology sector and 89.21% lower than that of the Health Care industry. The total asset for all United States stocks is 99.28% higher than that of the company.
Kronos Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kronos Bio's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kronos Bio could also be used in its relative valuation, which is a method of valuing Kronos Bio by comparing valuation metrics of similar companies.Kronos Bio is currently under evaluation in total asset category among its peers.
Kronos Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kronos Bio from analyzing Kronos Bio's financial statements. These drivers represent accounts that assess Kronos Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kronos Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.4B | 1.6B | 744.1M | 91.0M | 104.7M | 99.5M | |
| Enterprise Value | 1.4B | 1.2B | 438.4M | 46.2M | 53.1M | 50.4M |
Kronos Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Kronos Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kronos Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kronos Bio's value.| Shares | Hpm Partners Llc | 2024-09-30 | 410.8 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 406.8 K | Woodline Partners Lp | 2024-09-30 | 309.6 K | Choate Investment Advisors | 2024-09-30 | 308.7 K | Gentrust, Llc | 2024-09-30 | 295.2 K | Cm Management, Llc | 2024-09-30 | 200 K | Two Sigma Advisers, Llc | 2024-09-30 | 175.4 K | State Street Corp | 2024-09-30 | 171.2 K | Kennedy Capital Management Inc | 2024-09-30 | 137.2 K | Vida Ventures Advisors, Llc | 2024-09-30 | 2.8 M | Millennium Management Llc | 2024-09-30 | 2 M |
Kronos Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.49) % | ||||
| Current Valuation | (41.74 M) | ||||
| Shares Outstanding | 60.34 M | ||||
| Shares Owned By Insiders | 26.90 % | ||||
| Shares Owned By Institutions | 32.67 % | ||||
| Number Of Shares Shorted | 520.99 K | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 6.89 X | ||||
| Revenue | 6.29 M | ||||
| EBITDA | (121.83 M) | ||||
| Net Income | (112.67 M) | ||||
| Cash And Equivalents | 267.89 M | ||||
| Cash Per Share | 4.72 X | ||||
| Total Debt | 28.27 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 15.07 X | ||||
| Book Value Per Share | 2.70 X | ||||
| Cash Flow From Operations | (78.58 M) | ||||
| Short Ratio | 8.81 X | ||||
| Earnings Per Share | (1.43) X | ||||
| Target Price | 2.25 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.86 | ||||
| Market Capitalization | 57.93 M | ||||
| Total Asset | 213.28 M | ||||
| Retained Earnings | (508.86 M) | ||||
| Working Capital | 154.08 M | ||||
| Net Asset | 213.28 M |
About Kronos Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kronos Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kronos Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kronos Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Kronos Stock
Moving against Kronos Stock
| 0.59 | VCYT | Veracyte | PairCorr |
| 0.54 | VERA | Vera Therapeutics | PairCorr |
| 0.54 | DSGN | Design Therapeutics | PairCorr |
| 0.53 | VCEL | Vericel Corp Ord | PairCorr |
| 0.51 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Kronos Bio Piotroski F Score and Kronos Bio Altman Z Score analysis. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.